Beta adrenergic antagonists and antianginal drugs are used with the aim to ultimately
decrease mortality and enable patients to lead an improved quality of life by avoidance of …

Beta adrenergic antagonists and antianginal drugs are used with the aim to ultimately
decrease mortality and enable patients to lead an improved quality of life by avoidance of …

At present, there is no effective drug against the present coronavirus disease 2019 (COVID-
19) pandemic. It is known that severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Beta adrenergic antagonists and antianginal drugs are used with the aim to decrease
mortality and enable patients to lead an improved quality of life by avoidance of anginal …

Abstract Background Coronavirus disease 2019 (COVID-19), caused by a strain of
coronavirus known as severe acute respiratory syndrome coronavirus 2, is well known to …

The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide.
Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin …

More than 15 million people have been affected by coronavirus disease 2019 (COVID‐19)
and it has caused 640 016 deaths as of July 26, 2020. Currently, no effective treatment …

Overactivity of the renin-angiotensin-aldosterone system (RAAS) is a consistent feature of
COVID-19 as indicated by high concentrations of angiotensin II (Ang II) in lungs and other …

Background Alpha‐1 receptor antagonists may interfere with IL‐6 signaling and could
therefore be a potential treatment for COVID‐19. However, the effectiveness of these drugs …

Aims: To update our previously reported systematic review and meta‐analysis of
observational studies on cardiovascular drug exposure and COVID‐19 clinical outcomes by …